source
- Kairos pushes prostate cancer drug ENV-105 into earlier treatment line after promising mid-phase dataKairos Pharma announced a change to its phase 2 trial of ENV-105, a prostate cancer candidate, moving it to an earlier line of therapy. The modified protocol will enroll patients whose PSA rises a…
- Lycia Therapeutics files for IPO to fund antibody degrader platformLycia Therapeutics, a protein‑degradation startup built on research from Nobel laureate Carolyn Bertozzi, announced it has filed for an initial public offering. The filing is intended to raise cap…